Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10883476 | 0.84 | FNTA (0.32) | ALDH1A1TDP1FNTAFNTB | |
| SCHEMBL10883472 | 0.84 | FNTA (0.32) | ALDH1A1TDP1FNTAFNTB | |
| SCHEMBL3675154 | 0.84 | GRIK1 (0.33) | GRIK1GRIK2FNTAFNTB | |
| SCHEMBL17112013 | 0.83 | GRIK1 (0.35) | GRIK1GRIK2ALDH1A1FNTAFNTB | |
| SCHEMBL11027816 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL11027817 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL14639360 | 0.78 | — | — | |
| SCHEMBL2440971 | 0.78 | GRIK1 (0.41) | GRIK1GRIK2ALDH1A1TDP1FNTA | |
| SCHEMBL10878954 | 0.78 | GRIK1 (0.41) | GRIK1GRIK2ALDH1A1TDP1FNTA | |
| SCHEMBL11436935 | 0.77 | GRIK1 (0.34) | GRIK1GRIK2FNTAFNTBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| EP-4711010-A2 | PRO-PERFUME COMPOSITIONS | Firmenich SA (CH) | 2026-03-18 | — | — | EP | claimed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| US-12404479-B2 | Laundry detergent composition containing graft copolymer and benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | claimed |
| EP-4555060-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | The Procter & Gamble Company (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024213536-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | claimed |
| WO-2024156688-A1 | BIODEGRADABLE PERFUME COMPOSITION | GIVAUDAN SA (CH) | 2024-08-02 | — | — | WO | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| WO-2024011345-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2024-01-18 | — | — | WO | claimed |
| EP-2822682-A1 | MICROCAPSULES AND USES THEREOF | Firmenich SA (CH) | 2015-01-14 | — | — | EP | claimed |
| US-20140323376-A1 | MICROCAPSULES AND USES THEREOF | FIRMENICH SA (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2152673-B1 | 3- TO 7-MEMBERED 1,3-DIAZA-4-OXO-HETEROCYCLIC DERIVATIVES CAPABLE OF RELEASING ACTIVE ALDEHYDES OR KETONES | FIRMENICH & CIE (CH) | 2014-08-20 | — | — | EP | claimed |
| WO-2013079435-A1 | MICROCAPSULES AND USES THEREOF | FIRMENICH SA (CH) | 2013-06-06 | — | — | WO | claimed |
| EP-2430140-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132531-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-11-18 | — | — | WO | claimed |
| US-20100287710-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-11-18 | — | — | US | claimed |
| EP-2111443-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | The Procter and Gamble Company (US) | 2009-10-28 | — | — | EP | claimed |
| US-20080200363-A1 | Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost | PROECTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | claimed |
| WO-2008100601-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2008-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | GRIK1 4760/4885GRIK2 4773/4885ALDH1A1 2581/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | GRIK1 2489/4885GRIK2 2861/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.